Selective Bioactivity of Fungal Secondary Metabolites as a Framework for Targeted Drug Discovery
Introduction: Fungal secondary metabolites remain an important source of structurally diverse molecules with pharmacological potential, yet conventional natural-product discovery has often separated fungal biology, chemical discovery and biological screening into largely sequential activities. This separation can obscure metabolites that are produced only under particular ecological or culture conditions, promote repeated isolation of known compounds, and make it difficult to connect a biological phenotype with the constituent responsible for it. Objectives: The central argument of this Perspective is that selective bioactivity should be treated as an information-rich property of fungal metabolites rather than as a weaker form of broad-spectrum activity. Methods: We therefore propose an integrated framework that begins with ecological and taxonomic selection of fungal systems, assesses biosynthetic potential, actively explores metabolite expression, applies metabolomics and dereplication before extensive purification, and then links biological activity to chemical identity and mechanism. Results: The framework also reconciles phenotypic and target-based screening: phenotypic assays are valuable for discovering unexpected biology, whereas target-oriented assays become increasingly informative after a selective phenotype has been reproduced and chemically attributed. We distinguish five evidentiary stages—differential response, reproducibility, chemical attribution, mechanistic selectivity and pharmacological selectivity—and emphasize that genomic potential does not establish metabolite expression, metabolite detection does not establish biological activity, and biological activity does not establish drug candidacy. Conclusions: Thermophilic fungi, including Malbranchea cinnamomea, illustrate why environmental adaptation, cultivation conditions and chemical diversity should be incorporated into discovery design. The proposed framework is intended to move fungal natural-product research from activity-led isolation alone toward an integrated, evidence-linked strategy for targeted drug discovery.
Authors
- Shanthipriya Ajmera (ORCID: https://orcid.org/0000-0001-5105-5245)
Publication Details
- Journal
- Journal of chemical health risks
- Published
- 2026-11-13
- Primary Topic
- Microbial Natural Products and Biosynthesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00